evidence that grin2a mutations in melanoma correlate with decreased survival
Clicks: 241
ID: 195316
2014
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
241 views
75 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #153 of 207 articles by views in international journal of heat and technology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 207 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Previous whole-exome sequencing has demonstrated that melanoma tumours harbour mutations in the GRIN2A gene. GRIN2A encodes the regulatory GluN2A subunit of the glutamate-gated N-methyl-D-aspartate receptor (NMDAR), involvement of which in melanoma remains undefined. Here, we sequenced coding exons of GRIN2A in 19 low-passage melanoma cell lines derived from patients with metastatic melanoma. Potential mutation impact was evaluated in silico, including within the GluN2A crystal structure, and clinical correlations were sought. We found that of 19 metastatic melanoma tumours, four (21%) carried five missense mutations in the evolutionarily conserved domains of GRIN2A; two were previously reported. Melanoma cells that carried these mutations were treatment-naïve. SIFT analysis predicted that S349F, G762E and P1132L would disrupt protein function. When modelled into the crystal structure of GluN2A, G762E was seen to potentially alter GluN1-GluN2A interactions and ligand binding, implying disruption to NMDAR functionality. Patients whose tumours carried nonsynonymous GRIN2A mutations had faster disease progression and shorter overall survival (P < 0.05). This was in contrast to the BRAF V600E mutation, found in 58% of tumours but showing no correlation with clinical outcome (P = 0.963). Although numbers of patients in this study are small, and firm conclusions about the association between GRIN2A mutations and poor clinical outcome cannot be drawn, our results highlight the high prevalence of GRIN2A mutations in metastatic melanoma and suggest for the first time that mutated NMDARs impact melanoma progression.
| Reference Key |
d'mello2014frontiersevidence
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Stacey Ann N D'mello;Jack U Flanagan;Jack U Flanagan;Taryn N Green;Euphemia Y Leung;Marjan E Askarian-Amiri;Wayne R Joseph;Michael R McCrystal;Michael R McCrystal;Richard J Isaacs;James H F Shaw;Christopher E Furneaux;Matthew J During;Matthew J During;Graeme J FInlay;Bruce C Baguley;Maggie Lucy Kalev-Zylinska;Maggie Lucy Kalev-Zylinska |
| Journal | international journal of heat and technology |
| Year | 2014 |
| DOI |
10.3389/fonc.2013.00333
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.